Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3168

1.

Tumor inherent interferons: Impact on immune reactivity and immunotherapy.

Brockwell NK, Parker BS.

Cytokine. 2018 Apr 19. pii: S1043-4666(18)30150-9. doi: 10.1016/j.cyto.2018.04.006. [Epub ahead of print]

PMID:
29681426
2.

Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.

Yoshida S, Shime H, Takeda Y, Nam JM, Takashima K, Matsumoto M, Shirato H, Kasahara M, Seya T.

Cancer Sci. 2018 Apr;109(4):956-965. doi: 10.1111/cas.13543. Epub 2018 Mar 25.

3.

Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod.

Rocco R, Alegre N, Pozner R, Wainstok R, Gazzaniga S.

Toxicol Lett. 2018 May 15;288:82-88. doi: 10.1016/j.toxlet.2018.01.016. Epub 2018 Feb 2.

PMID:
29410238
4.

A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-anal 5% Imiquimod in HIV-1-Infected Men With High-Grade Squamous Intraepithelial Lesions.

Cranston RD, Baker JR, Siegel A, Brand RM, Janocko L, McGowan I.

Dis Colon Rectum. 2018 Mar;61(3):298-305. doi: 10.1097/DCR.0000000000000991.

PMID:
29360679
5.

Synergistic effects of stellated fibrous mesoporous silica and synthetic dsRNA analogues for cancer immunotherapy.

Wang X, Li X, Ito A, Sogo Y, Watanabe Y, Hashimoto K, Yamazaki A, Ohno T, Tsuji NM.

Chem Commun (Camb). 2018 Jan 25;54(9):1057-1060. doi: 10.1039/c7cc08222c.

PMID:
29323387
6.

PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Langut Y, Talhami A, Mamidi S, Shir A, Zigler M, Joubran S, Sagalov A, Flashner-Abramson E, Edinger N, Klein S, Levitzki A.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13655-13660. doi: 10.1073/pnas.1714587115. Epub 2017 Dec 11.

7.

TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling.

Chen Y, Zhao J, Li D, Hao J, He P, Wang H, Zhang M.

Yonsei Med J. 2018 Jan;59(1):43-50. doi: 10.3349/ymj.2018.59.1.43.

8.

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA, Smith KT, Olson WC, Fanous IS, Nail CJ, Brenin CM, Hall EH, Slingluff CL Jr.

J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.

9.

Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.

Lee J, Liao R, Wang G, Yang BH, Luo X, Varki NM, Qiu SJ, Ren B, Fu W, Feng GS.

Cell Rep. 2017 Nov 14;21(7):1870-1882. doi: 10.1016/j.celrep.2017.10.064.

10.

Inflammatory memory sensitizes skin epithelial stem cells to tissue damage.

Naik S, Larsen SB, Gomez NC, Alaverdyan K, Sendoel A, Yuan S, Polak L, Kulukian A, Chai S, Fuchs E.

Nature. 2017 Oct 26;550(7677):475-480. doi: 10.1038/nature24271. Epub 2017 Oct 18. Erratum in: Nature. 2018 Jul 4;:.

11.

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.

Bostanci S, Kocyigit P, Vural S, Heper AO, Botsali A.

Dermatol Surg. 2018 Jan;44(1):36-41. doi: 10.1097/DSS.0000000000001266.

PMID:
29016542
12.

Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.

Read T, Webber S, Thomas J, Wagels M, Schaider H, Soyer HP, Smithers BM.

BMJ Open. 2017 Oct 6;7(10):e016816. doi: 10.1136/bmjopen-2017-016816.

13.

Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis.

Tranoulis A, Laios A, Mitsopoulos V, Lutchman-Singh K, Thomakos N.

Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:129-136. doi: 10.1016/j.ejogrb.2017.09.020. Epub 2017 Sep 27. Review.

PMID:
28985547
14.

Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream.

Salman A, Sarac G, Can Kuru B, Cinel L, Yucelten AD, Ergun T.

Pediatr Dermatol. 2017 Nov;34(6):e302-e304. doi: 10.1111/pde.13283. Epub 2017 Sep 21.

PMID:
28940760
15.

Type I interferons in the pathogenesis and treatment of canine diseases.

Klotz D, Baumgärtner W, Gerhauser I.

Vet Immunol Immunopathol. 2017 Sep;191:80-93. doi: 10.1016/j.vetimm.2017.08.006. Epub 2017 Aug 26. Review.

PMID:
28895871
16.

Exploiting poly(I:C) to induce cancer cell apoptosis.

Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L.

Cancer Biol Ther. 2017 Oct 3;18(10):747-756. doi: 10.1080/15384047.2017.1373220. Epub 2017 Sep 7. Review.

17.

Topical Imiquimod for Melanoma In Situ? A Word of Caveat.

Wehkamp U, Schwarz T.

Dermatol Surg. 2018 Apr;44(4):582-583. doi: 10.1097/DSS.0000000000001253. No abstract available.

PMID:
28872561
18.

Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.

Badavanis G, Pasmatzi E, Monastirli A, Georgiou S, Tsambaos D.

Acta Dermatovenerol Croat. 2017 Jul;25(2):164-166.

PMID:
28871935
19.

Neuroendocrine Modulation of IL-27 in Macrophages.

Roewe J, Higer M, Riehl DR, Gericke A, Radsak MP, Bosmann M.

J Immunol. 2017 Oct 1;199(7):2503-2514. doi: 10.4049/jimmunol.1700687. Epub 2017 Aug 23.

PMID:
28835457
20.

Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments.

Pellegrini C, Orlandi A, Costanza G, Di Stefani A, Piccioni A, Di Cesare A, Chiricozzi A, Ferlosio A, Peris K, Fargnoli MC.

PLoS One. 2017 Aug 22;12(8):e0183415. doi: 10.1371/journal.pone.0183415. eCollection 2017.

Supplemental Content

Loading ...
Support Center